Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for Long-Term control of cushing syndrome

NCT ID NCT03604198

Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 4 times

Summary

This study looks at the long-term safety of relacorilant, a drug for people with Cushing syndrome. It includes 125 adults who previously completed a relacorilant study and may benefit from continued treatment. Researchers will track side effects over time to see if the drug is safe for extended use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
relacorilant
What this could lead to
If successful, this could provide a long-term treatment option for managing Cushing syndrome symptoms.
What could go wrong
This is an early-phase extension study focused on safety, not effectiveness. It may not lead to a new treatment, and side effects are possible.
Why investors are watching

Corcept Therapeutics is running an open-label extension study of relacorilant, a drug for endogenous Cushing syndrome, in 125 patients who already completed an earlier Corcept trial. For a small company, this long-term safety data matters because it could support the drug's approval and broaden its use. A positive result would strengthen Corcept's position in a niche market, while a safety problem could set back the drug's development.

If it works: If the trial shows relacorilant is safe over the long term, Corcept could use the data to support regulatory approval and expand the drug's label. That could make relacorilant a more established treatment option for Cushing syndrome patients.

If it fails: If the trial reveals safety issues or fails to confirm long-term tolerability, regulators may delay or reject the drug. Clinical trials often fail, and a setback here could hurt Corcept's pipeline and its prospects as a small company.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

125 people

The number who actually took part.

Started

May 2018

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Major Inclusion Criteria: * Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome * According to the Investigator's opinion will benefit from continuing treatment with relacorilant. Exclusion Criteria: * Major Exclusion Criteria: * Premature discontinuation from a relacorilant parent study * Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cushing syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ACTH-dependent Cushing syndrome adrenal carcinoma adrenal cortex neoplasm Cushing syndrome ectopic ACTH secretion syndrome endogenous Cushing syndrome hypertensive disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cushing syndrome

Contacts and locations

Locations

  • Site 1

    Indianapolis, Indiana, 46202, United States

  • Site 10

    Atlanta, Georgia, 30318, United States

  • Site 11

    Dallas, Texas, 75390, United States

  • Site 12

    Houston, Texas, 77079, United States

  • Site 13

    Fall River, Massachusetts, 02721, United States

  • Site 16

    Munich, Germany

  • Site 17

    Madrid, 28007, Spain

  • Site 18

    Girona, Spain

  • Site 19

    Seville, Spain

  • Site 2

    Pittsburgh, Pennsylvania, 15212, United States

  • Site 21

    Naples, 80131, Italy

  • Site 24

    New York, New York, 10021, United States

  • Site 25

    Milan, 20145, Italy

  • Site 27

    Baltimore, Maryland, 21287, United States

  • Site 28

    Bucharest, 11863, Romania

  • Site 29

    Tel Aviv, 64239, Israel

  • Site 3

    St Louis, Missouri, 63110, United States

  • Site 31

    Bucharest, 10825, Romania

  • Site 32

    Fort Worth, Texas, 76132, United States

  • Site 33

    Rotterdam, 3015 GD, Netherlands

  • Site 34

    Jackson, Mississippi, 39202, United States

  • Site 35

    Stanford, California, 94305, United States

  • Site 36

    Rochester, Minnesota, 55905, United States

  • Site 37

    Bucharest, 050474, Romania

  • Site 38

    Málaga, 29006, Spain

  • Site 39

    Torrance, California, 90502, United States

  • Site 4

    Wilmington, North Carolina, 28401, United States

  • Site 40

    Ancona, 60126, Italy

  • Site 42

    Würzburg, 97080, Germany

  • Site 43

    Cleveland, Ohio, 44195, United States

  • Site 45

    Lublin, 20412, Poland

  • Site 46

    Pittsburgh, Pennsylvania, 15213, United States

  • Site 47

    Krakow, 30-688, Poland

  • Site 48

    Padova, 35128, Italy

  • Site 49

    Phoenix, Arizona, 85013, United States

  • Site 5

    Metairie, Louisiana, 70006, United States

  • Site 50

    Miami, Florida, 33136, United States

  • Site 51

    Nova Scotia, Canada

  • Site 53

    Alicante, Spain

  • Site 55

    Reno, Nevada, 89511, United States

  • Site 6

    Albany, New York, 12206, United States

  • Site 7

    El Paso, Texas, 79935, United States

  • Site 8

    Ann Arbor, Michigan, 48109, United States

  • Site 9

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.